Bortezomib VRD regimen

VRDregimen is a multi-drug combination treatment regimen, usually used to treat malignant hematological tumors such as multiple myeloma (Multiple Myeloma). VRD represents the three drugs used in the protocol, namely bortezomib (Bortezomib), rituximab (Lenalidomide) and dexamethasone (Dexamethasone). This approach aims to attack cancer cells simultaneously through different mechanisms to improve treatment effectiveness.

1.Bortezomib (Bortezomib): Bortezomib is a proteasome inhibitor that prevents the growth and proliferation of cancer cells by interfering with protein degradation in cancer cells. This is a targeted therapy drug that is particularly useful in multiple myeloma because this cancer is often accompanied by abnormal plasma cell proliferation.

2.Rituximab (Lenalidomide): Rituximab is an immunomodulator that can improve the function of the immune system and help the body fight cancer cells. In addition, it can inhibit the proliferation of cancer cells. This is an oral medication that is usually taken daily.

3.Dexamethasone (Dexamethasone): Dexamethasone is a glucocorticoid that has anti-inflammatory and anti-cancer effects. In a VRD regimen, dexamethasone is usually taken by mouth or by injection to reduce symptoms, control inflammation, and improve treatment effectiveness.

The advantage of the VRD program is that it combines drugs with different mechanisms to attack cancer cells from multiple aspects, thus improving the success rate of treatment. It has become widely used in patients with multiple myeloma, especially at initial diagnosis and in the treatment of relapses. However, because every patient's situation is different, treatment options may need to be individualized based on the specific situation.

Bortezomib is already on the market in China and has been included in medical insurance. Patients can purchase it domestically at a price of around 3,000 to 4,000 yuan. Please consult the local hospital pharmacy for specific prices and reimbursement policies. The cheaper ones abroad are mainly Indian generic drugs, which cost around 1,000 yuan and have basically the same ingredients as the domestic bortezomib drug.